Encaleret
CLTX-305-303
Phase 3 small_molecule active
Quick answer
Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1) is a Phase 3 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active